Century Therapeutics Inc. (NASDAQ:IPSC) is one of the best fast growing penny stocks to buy according to analysts. On January 20, Piper Sandler increased its price target for Century Therapeutics to $4 from $2 with an Overweight rating, citing the company’s plan to submit an IND for CNTY-813 this year and deliver initial data by 2027. Additionally, the firm highlighted Century’s strong financial position, estimating a pro forma cash balance of approximately $267 million that is expected to fund operations ...

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - TechCreate Group Ltd. (TCGL) is up 99% at $205.71 - VivoSim Labs, Inc. (VIVS) is up 74% at $2.96 - La Rosa Holdings Corp. (LRHC) is up 55% at $4.66 - Sandisk Corporation (SNDK) is up 23% at $668.13 - Springview Holdings Ltd (SPHL) is up 19% at $4.76 - BUUU Group Limited (BUUU) is up 16% at $10.86 - Deckers Outdoor Corporation (DECK) is up 11% at $111.64 - Lumentum Holdings Inc. (LITE) is up 10% at $419.58 - Chanson International Holding (CHSN) is up 10% at $2.15 - Century Therapeutics, Inc. (IPSC) is up 9% at $2.20 [3] Premarket Losers - Kaixin Holdings (KXIN) is down 43% at $5.70 - Brand Engagement Network, Inc. (BNAI) is down 32% at $35.56 - PennyMac Financial Services, Inc. (PFSI) is down 21% at $117.50 - Schneider National, Inc. (SNDR) is down 19% at $24.05 - Moolec Science SA (MLEC) is down 19% at $5.23 - Nuwellis, Inc. (NUWE) is down 18% at $3.43 - Digital Currency X Technology Inc. (DCX) is down 16% at $3.44 - Serina Therapeutics, Inc. (SER) is down 15% at $3.03 - Namib Minerals (NAMM) is down 11% at $5.00 - ZeroStack Corp. (ZSTK) is down 6% at $11.00 [4]

Century Therapeutics, Inc. (IPSC) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the sy ...

PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced it has entered into a securities purchase agreement for a private placement for initial gross proceeds of approximately $135 million to the Company, before placement agent fees and offering expenses. The financing is being led by new investor TCGX, and includes p ...

Core Viewpoint - Momentum investing focuses on "buying high and selling higher," contrasting with traditional strategies of "buying low and selling high" [1] Group 1: Momentum Investing Strategy - Investors following momentum investing tend to avoid undervalued stocks, believing that quicker profits can be made from trending stocks [1] - Identifying the right entry point for fast-moving stocks can be challenging, as these stocks may lose momentum if their growth potential does not justify their high valuations [1] Group 2: Investment Opportunities - The Zacks Momentum Style Score is useful for identifying strong momentum stocks, while the 'Fast-Paced Momentum at a Bargain' screen helps find attractively priced stocks with momentum [2] - Century Therapeutics, Inc. (IPSC) is highlighted as a strong candidate, having experienced a 3.9% price increase over the past four weeks [3] Group 3: Performance Metrics - IPSC has shown a 14.6% price gain over the past 12 weeks, indicating strong momentum, with a beta of 1.8, suggesting it moves 80% more than the market [4] - IPSC has a Momentum Score of B, indicating a favorable time to invest based on its momentum [5] Group 4: Earnings and Valuation - An upward trend in earnings estimate revisions has contributed to IPSC's Zacks Rank 2 (Buy), which is associated with strong momentum effects [6] - IPSC is trading at a Price-to-Sales ratio of 0.43, suggesting it is undervalued, as investors pay only 43 cents for each dollar of sales [6] Group 5: Additional Investment Options - Besides IPSC, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, presenting further investment opportunities [7] - Zacks offers over 45 Premium Screens tailored to different investing styles, aiding in stock selection [8]

Core Insights - Century Therapeutics has appointed Dr. Han Lee and Dr. Martin Murphy to its Board of Directors, enhancing its leadership team at a critical time for the company [1][2] Company Overview - Century Therapeutics is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-derived cell therapies aimed at treating autoimmune diseases and cancer [4] - The company utilizes its iPSC cell foundry and a novel immune evasion engineering technology called Allo-Evasion™ to create off-the-shelf cell therapies, which are expected to improve patient access and offer advantages over existing therapies [4] Leadership Appointments - Dr. Han Lee will serve on the Audit and Compensation Committees, bringing extensive experience in capital formation and corporate development from his previous roles at ImmPACT Bio, Neogene Therapeutics, and AstraZeneca [1][2] - Dr. Martin Murphy will be part of the Compensation and Nominating and Corporate Governance Committees, with a strong background in life science investment and company creation from his roles at Syncona and MVM Life Science Partners [1][3] Strategic Focus - The company is prioritizing the advancement of its iPSC-derived cell therapy programs, particularly CNTY-813, which is being developed as a potentially curative treatment for type 1 diabetes [2]

Summary of Century Therapeutics FY Conference Call Company Overview - **Company**: Century Therapeutics (NasdaqGS: IPSC) - **Focus**: Development of induced pluripotent stem cells (iPSCs) for CAR T cells and natural killer (NK) cells targeting autoimmune diseases and cancer [1][2] Key Developments - **CNTY813**: New program for iPSC-derived beta islet cells aimed at treating type 1 diabetes [1] - **CNTY308**: A CD19 CAR-iT cell therapy that is being developed for autoimmune diseases [1][19] Core Advantages of iPSC-Derived Therapies 1. **Engineerability**: Ability to harness synthetic biology for cell therapy [4] 2. **Characterization and Reproducibility**: High control over the differentiation process of iPSCs [4] 3. **Profitable Scalability**: Pathway to achieve antibody-like scale and cost efficiency [5] Alloevasion Technology - **Definition**: A set of genetic edits that allow iPSC-derived cells to coexist with the patient's immune system [6] - **Key Features**: - Removal of HLAs to prevent T cell engagement [7] - Introduction of a universal NK cell inhibitory ligand for protection against NK cells [8] - IgG degrading protease to mitigate antibody-mediated immunity [9][10] Clinical Development Plans - **CNTY813**: On track for IND-enabling stages by the end of 2025, with tumorigenicity studies underway [18] - **CNTY308**: Clinical trials planned to initiate next year, focusing primarily on autoimmune diseases [23][24] Market Opportunity - **Type 1 Diabetes**: Approximately 2 million patients in the U.S. and 9 million worldwide, presenting a significant unmet medical need [32] - **Autoimmune Diseases**: Over 50 million patients in the U.S., indicating a large potential market for CNTY308 [22] Partnerships and Future Plans - Continuous dialogue with pharmaceutical companies for potential partnerships, especially in Type 1 diabetes and autoimmune disease markets [31][32] - Exploration of regenerative medicine opportunities, including potential applications in Parkinson's disease and cardiac disease [36][38] Financial Position - **Cash Reserves**: Approximately $133 million, expected to fund operations into Q4 2027 [39] - **Upcoming Catalysts**: Clinical data generation for CNTY101 and CNTY308, and IND submission for type 1 diabetes expected in 2026 [39] Conclusion Century Therapeutics is positioned at the forefront of iPSC-derived cell therapies, with innovative approaches to address significant medical needs in autoimmune diseases and type 1 diabetes. The company's focus on Alloevasion technology and scalable manufacturing processes enhances its potential for success in the competitive biotech landscape.

Core Insights - Century Therapeutics is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-derived cell therapies targeting autoimmune diseases and cancer [2] Company Participation - Century Therapeutics will participate in the Piper Sandler 37th Annual Healthcare Conference in New York, with a live webcast available on the company's Investors page [1] - An archived replay of the webcast will be accessible for at least 30 days following the event [1] Leadership Engagement - Chad Cowan, Ph.D., Chief Scientific Officer, will join the "State of the Art in Cell Therapy" panel discussion on December 2, 2025 [3] - Brent Pfeiffenberger, Pharm.D., Chief Executive Officer, and Dr. Cowan will participate in a webcasted fireside chat on December 3, 2025 [3] Technology and Approach - The company utilizes its iPSC cell foundry and the Allo-Evasion™ technology to develop off-the-shelf cell therapies, aiming to enhance patient access and improve upon existing therapies [2]

Financial Performance - Century Therapeutics reported a net loss of $34.4 million for Q3 2025, compared to a net loss of $31.2 million in Q3 2024, reflecting a year-over-year increase in losses of approximately 7.3%[7] - Research and Development (R&D) expenses decreased to $22.5 million in Q3 2025 from $27.2 million in Q3 2024, a reduction of about 17.3%[6] - General and Administrative (G&A) expenses were $6.8 million for Q3 2025, down from $8.4 million in Q3 2024, representing a decrease of approximately 19%[6] - Total assets decreased to $244.7 million as of September 30, 2025, from $353.2 million as of December 31, 2024, a decline of approximately 30.7%[12] Cash Position - Cash, cash equivalents, and marketable securities totaled $132.7 million as of September 30, 2025, down from $220.1 million as of December 31, 2024, indicating a decrease of about 39.7%[6] - The company estimates its cash runway will support operations into the fourth quarter of 2027[4] Clinical Development - The company anticipates initiating IND-enabling studies for its lead beta islet program, CNTY-813, by the end of 2025, with an IND submission planned for as early as 2026[4] - CNTY-308 is progressing through IND-enabling studies, with clinical study initiation expected in 2026[4] - Century Therapeutics has generated compelling preclinical data for its iPSC-derived beta islet program, indicating potential for rapid and sustained glucose control without chronic immune suppression[3] - Initial clinical data from the CNTY-101 trial in CARAMEL is expected to be presented on December 5, 2025[6]

Development Programs - The company is developing CNTY-813 for Type 1 diabetes, with plans to move into IND-enabling studies by the end of 2025 and anticipate IND submission as early as 2026[140] - CNTY-308, a CD19-targeted CAR-iT cell therapy, is progressing towards clinical studies expected to start in 2026 following successful IND-enabling studies[141] Financial Performance - The company has not generated any revenue from product sales and does not expect to do so in the foreseeable future, relying on future collaborations for revenue[158] - Collaboration revenue for the nine months ended September 30, 2025, was $109.2 million, a significant increase from $2.4 million in 2024[176] - Total operating expenses for the three months ended September 30, 2025, were $36.1 million, slightly higher than $35.6 million in 2024[168] - Research and development expenses decreased to $22.5 million for the three months ended September 30, 2025, from $27.2 million in 2024, a reduction of $4.7 million[170] - General and administrative expenses were $6.8 million for the three months ended September 30, 2025, down from $8.4 million in 2024[171] - Interest income decreased to $1.6 million for the three months ended September 30, 2025, compared to $3.3 million in 2024[173] - The accumulated deficit as of September 30, 2025, was $772.7 million[183] Cash Flow and Financing - As of September 30, 2025, the company had cash and cash equivalents of $55.5 million and investments of $77.2 million[183] - The company anticipates needing to raise additional financing in the future to support ongoing operations and clinical trials[146] - Net cash used in operating activities was $87.8 million for the nine months ended September 30, 2025, compared to $85.9 million for the same period in 2024, reflecting a net income of $9.6 million and non-cash charges of $23.1 million[190] - Net cash provided by investing activities increased significantly to $85.1 million for the nine months ended September 30, 2025, from $16.9 million in the same period of 2024, primarily due to the sale of fixed maturity securities of $121.7 million[192] - Net cash provided by financing activities decreased to $0.1 million for the nine months ended September 30, 2025, down from $75.2 million in 2024, which included $17.8 million from an at-the-market capital raise and $56.6 million from PIPE financing[194] - The company reported a net decrease in cash, cash equivalents, and restricted cash of $2.5 million for the nine months ended September 30, 2025, compared to an increase of $6.1 million in 2024[189] - As of September 30, 2025, the company had cash, cash equivalents, and restricted cash totaling $58.7 million, along with investments of $77.2 million[206] Operational Changes - The company completed a workforce reduction of approximately 51% to focus on key clinical programs[143] - Bristol-Myers Squibb terminated its collaboration agreement effective March 12, 2025, which included a $100 million upfront payment and stock purchase[149] - The company is investing in manufacturing capabilities to improve efficiency and scalability of its iPSC cell therapy products[145] - Future capital requirements will depend on various factors, including the costs of clinical trials and regulatory approvals for current and future product candidates[187] - The company has significant contractual obligations totaling $66.4 million, with $7.99 million due within one year and $14.8 million due in the next one to three years[196] - The company experienced a $120.5 million decrease in net operating assets and liabilities during the nine months ended September 30, 2025, primarily due to a decrease in deferred revenue from the termination of a collaboration agreement[190] Economic Factors - Inflation has not had a material effect on the company's financial statements, although it has increased costs related to labor and laboratory consumables[208] - Future disruptions in financial institutions could adversely affect the company's ability to access cash and cash equivalents[207] - The company is classified as an "emerging growth company" under the JOBS Act, allowing it to take advantage of reduced reporting requirements[198]